Abstract The purpose of this study was to assess the performance of Cepheid® Xpert MTB/RIF® ("Xpert") and TBBiochip® MDR ("TB-Biochip"). Sputum specimens from adults with presumptive tuberculosis (TB) were homogenized and split for: (1) direct Xpert and microscopy, and (2) concentration for Xpert, microscopy, culture [Lowenstein-Jensen (LJ) solid media and Mycobacteria Growth Indicator Tube® (MGIT)], indirect drug susceptibility testing (DST) using the absolute concentration method and MGIT, and TB-Biochip. In total, 109 of 238 (45.8 %) specimens were culture-positive for Mycobacterium tuberculosis complex (MTBC), and, of these, 67 isolates were rifampicin resistant (RIF-R) by 
Introduction
Tuberculosis (TB) is an infectious disease caused by the bacillus Mycobacterium tuberculosis, with an estimated 8.8 million new cases and 1.5 million deaths in 2010 [1] . Russia ranks among 22 countries in the world with the largest burden of TB, including one of the highest rates of drug-resistant TB [1] . According to nationwide surveillance data collected in 2009, 15.5 % of not previously treated cases and 33.7 % of previously treated TB cases in Russia were identified as multidrug-resistant (MDR) TB, and rates continue to rise [2] .
Rapid detection of MDR TB would be optimal for patient management, but is hampered by the limitations and delays associated with the primary methods available for the diagnosis of TB. Significant advances have been made in the rapid and accurate diagnosis of TB and drug resistance with the advent of molecular methods. The TB-Biochip® MDR ("TB-Biochip") system (Biochip-IMB Ltd., Moscow, Russia), developed at the Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia, is based on a multiplex polymerase chain reaction (PCR) followed by hybridization on a platform of gel-based oligonucleotide microarrays (biochips) that simultaneously detects DNA specific for Mycobacterium tuberculosis complex (MTBC) and mutations that cause rifampicin (RIF) and isoniazid (INH) resistance from either culture isolates or clinical specimens in less than 12 h [3, 4] . It is used primarily in Russia and in neighboring countries that were part of the former Soviet Union. However, because TB-Biochip is labor intensive, technically demanding, and requires specialized laboratory infrastructure, its utility is limited to reference laboratories. At the same time, batch-testing increases the turn-around time, thereby, reducing its clinical utility. More recently, technical progress has resulted in simplified diagnostic tools that overcome several drawbacks of earlier nucleic acid amplification tests (NAAT). The Cepheid® Xpert MTB/RIF® test ("Xpert", Cepheid Inc., Sunnyvale, CA, USA) is an automated on-demand assay that detects MTBC-specific DNA and mutations associated with RIF resistance directly from sputum within 2 h. It does not require bio-containment infrastructure or molecular expertise to perform [5, 6] . The test utilizes PCR and molecular beacon technology within a closed-system cartridge that integrates sample preparation, DNA extraction, amplification, and detection, with minimal risk of contamination.
Our project aimed to: (1) validate the Xpert test using both unconcentrated and concentrated portions of a single sputum specimen by comparing the results with direct and concentrated microscopy, conventional solid or liquid culture, and indirect phenotypic drug susceptibility testing (DST) methods, and (2) compare the results from a subset of specimens to those obtained by TB-Biochip for the detection of MTBC and rifampicin resistance directly from sputum.
Materials and methods
Project settings, patients, and specimens Specimens were collected as part of routine medical care from patients at two sites in Russia: (1) the Central TB Research Institute (CTRI) of the Russian Academy of Medical Sciences in Moscow, where the majority of patients are referred with chronic, often drug-resistant, TB, and (2) the Regional TB Dispensary in Vladimir Oblast, where both hospitalized and ambulatory patients from within the region are treated. Microbiology testing was performed at each site by its respective laboratory. Internal quality control and external quality assessment practices are followed by both laboratories with equally high performance.
Sputum samples of at least 5.0 ml were collected from consecutively evaluated adults (≥18 years old) with presumptive or recently diagnosed pulmonary TB between July and October 2011. Patients having received anti-TB drugs within 60 days prior to specimen collection were excluded. The final diagnosis, based on the clinical and radiographic findings and microbiology results from all specimens obtained from the patient during this illness episode, was assigned by a panel of physicians according to explicit clinical definitions and documented for each specimen. Because the purpose of this project was to evaluate Xpert test performance in these two laboratories, the results were not reported to the physician and did not influence patient management decisions. Upon review, the U.S. Centers for Disease Control and Prevention (CDC) determined this evaluation to be a laboratory test validation project and not human subject research. The local sites in Russia relied on the CDC determination.
Laboratory methods
After the addition of 0.5 ml sterile distilled water and glass beads, each specimen was homogenized for 60-90 s with a vortex unit and split into two portions (Fig. 1) . From one portion, 1.0 ml was tested by Xpert and a smear prepared for Ziehl-Neelsen (ZN) microscopy [7] . The remaining portion (≥3 ml) was decontaminated with N-acetyl-L-cysteine/sodium hydroxide (BBL MycoPrep; BD, Sparks, MD, USA) [7] and centrifuged at 3,000×g for 15 min. After centrifugation, the supernatant was decanted and the sediment was resuspended in 3.0 ml of phosphate-buffered saline (pH 6.8), from which 0.5 ml was tested with Xpert, 0.2 ml was inoculated onto Lowenstein-Jensen (LJ), 0.5 ml onto BACTEC Mycobacteria Growth Indicator Tube® (MGIT) 960 system (BD, Sparks, MD, USA) culture media, and a smear prepared for auraminerhodamine fluorescence microscopy [7] .
Smears were scored using the World Health Organization (WHO) scale [8] . Acid-fast bacillus (AFB)-positive cultures were confirmed to be MTBC by the MTBc ID test (BD, Sparks, MD, USA) [9] or conventional biochemical tests performed according to standard protocols [7] . For culture confirmation of MTBC, the CTRI laboratory also employed a real-time PCR assay using primers directed against IS6110, followed by detection with fluorescent-labeled probes specific for MTBC (Amplitub-Rv, Syntol, Moscow, Russia) [10, 11] . Culture-based DST was performed by either the BACTEC MGIT 960 system [12] or the absolute concentration method on LJ medium [13] using standard critical concentrations of 1.0 mcg/ml and 40.0 mcg/ml for rifampicin, and critical concentrations of 0.1 mcg/ml and 0.2 mcg/ml for isoniazid, respectively.
The Xpert assay was performed according to the manufacturer's instructions. The results were obtained using the Xpert MTB/RIF software, version 4.0.
At the CTRI laboratory only, in addition to the above procedures, a portion of the resuspended sediment (0.5 ml) was also tested with the TB-Biochip assay according to the manufacturer's specifications. The presence and nature of mutations were determined by analysis of the fluorescence intensity pattern on the chip, using a fluorescence analyzer equipped with ImageWare software (Biochip-IMB Ltd., Moscow, Russia) [3, 4] .
Data analysis
The data were entered into an Epi Info version 3.3.5 (CDC, Atlanta, GA, USA) database. Statistical analyses were performed using SAS software, version 9.1 (SAS Institute Inc., Cary, NC, USA). The sensitivity and specificity of direct and concentrated Xpert, TB-Biochip, and smear microscopy for MTBC detection were calculated using (1) culture positivity in the same specimen as the reference standard and (2) the patient's final diagnosis (based on all available clinical, radiographic, as well as microbiologic information). These reference standards were applied to all specimens included in this evaluation. The sensitivity and specificity of direct and concentrated Xpert as well as TB-Biochip for the detection of RIF resistance was calculated using as the reference standard: (1) the absolute concentration method on LJ; (2) the BACTEC MGIT 960 result; and (3) combined results of DST on LJ and MGIT when RIF resistance was defined as resistance by either LJ and/or MGIT DST methods, RIF susceptibility defined as susceptible by both LJ and MGIT methods, or by either method when only the results from one method were available.
Specimens from cases with non-tuberculous mycobacteria (NTM) were included in the calculation of the specificity of Xpert. Contaminated cultures were excluded for the 5ml raw, unconcentrated sputum Add 0.5 ml sterile distilled water and homogenize using a vortex with glass beads Xpert assay and TB-Biochip sensitivity and specificity calculations.
Results

Specimens
A total of 238 specimens from 201 consecutive patients with presumptive TB were tested using the Xpert and conventional methods (134 in Vladimir; 104 at CTRI). Of the 238 specimens, 109 (45.8 %) were culture-positive (liquid or solid) for MTBC, 65 were direct smear-positive, 93 were concentrated smear-positive, and NTM were isolated from four specimens (two were M. kansasii, one M. avium, and one M. scrofulaceum). Of 109 culture-positive specimens, 67 (61.5 %) were found to be rifampicin-resistant by phenotypic DST, and 64 of these (95.5 %) were also resistant to isoniazid.
Comparison of direct Xpert assay with microscopy and culture results for the detection of MTBC
In total, 230 of 238 (96.6 %) specimens gave an interpretable result with the direct Xpert assay: 119 were positive, 111 were negative, and eight (3.4 %) were uninterpretable. (Table 1) . Among 121 specimens with negative liquid and solid culture MTBC result and available direct Xpert result, 104 were MTB-negative by direct Xpert, i.e., the specificity of direct Xpert was 86.0 % (Table 1) . Seventeen specimens that were culture-negative for MTBC tested positive by the direct Xpert assay: 11 of these 17 specimens were from patients who were subsequently classified as TB patients (seven based on positive laboratory results from specimens collected outside of the project and four based on their final diagnosis). Of the remaining six patients, three were suspected of TB relapse, and TB was ruled out in the other three patients based on clinical and bacteriological criteria. The specificity of direct Xpert for excluding TB was 89.3 % (50 of 56) when the final diagnosis was used as the reference standard. None of the four NTM specimens were positive in the Xpert assay. The indeterminate rate (3.4 %, 8/238) for direct Xpert was lower than the MGIT contamination rate (4.2 %, 10/ 238) but higher than that of solid media (2.1 %, 5/236). The overall sensitivity of Xpert (94.5 %, 103/109) was not significantly affected when concentrated specimens were tested, but the indeterminate rate was reduced to zero. The median time from specimen receipt to the reporting of MTBC from MGIT was 10 days [interquartile range (IQR): 7, 15) and 24 days (IQR: 18, 34) from LJ culture, compared to same-day results using Xpert.
Comparison of direct Xpert results with phenotypic DST results for the detection of RIF resistance Xpert correctly detected rifampicin resistance-associated mutations in 55 of 56 (98.2 %) specimens when compared with the MGIT results, and in 45 of 50 (90.0 %) specimens when compared with those obtained by LJ DST. RIF resistance-associated mutations were not identified by Xpert in 42 of 44 (95.5 %) specimens that were RIF susceptibile by MGIT and in 28 of 30 (93.3 %) that were RIF susceptible by LJ ( Table 2 ). The overall concordance between Xpert and phenotypic methods to detect RIF resistance was 97.0 % (97/100) with MGIT and 91.3 % (73/80) with LJ. The rate of isoniazid resistance in phenotypically RIF-resistant specimens was 95.5 % (64/67). Given the 98.2 % sensitivity for the detection of rifampicin resistance by Xpert compared to MGIT, 93.8 % of MDR TB specimens were identified by the Xpert assay.
Of eight specimens with discordant RIF results between Xpert and phenotypic DST, three had mutations in the rpoB gene by Xpert and were susceptibile by either culture-based method (Table 3) . Five specimens were found not to have rpoB gene mutations by Xpert but were phenotypically resistant. Six of these eight discordant isolates were further tested by TB-Biochip and all the results coincided with the Xpert results. The median time from specimen receipt to the completion of phenotypic DST was 22 (IQR: 16, 30) and 52 days (IQR: 46, 64) for MGIT and LJ, respectively.
Performance of TB-Biochip
At the CTRI laboratory, a portion of each concentrated specimen was also tested with the TB-Biochip assay. Of the 104 specimens tested, 71 (68.3 %) were culturepositive for MTBC; 80.3 % (57/71) were RIF-resistant and 87.3 % (62/71) were INH-resistant by phenotypic DST. TBBiochip for the detection of MTBC in culture-positive specimens had an overall sensitivity of 97.3 % (69/71) [100 % (64/64) for smear-positive and 71.4 % (5/7) for smearnegative specimens]; the specificity was 78.1 % (25/32) in culture-negative specimens (Table 1) .
For the detection of rifampicin resistance, the sensitivity of TB-Biochip was 100 % (50/50) when compared with the MGIT DST results and 90.9 % (40/44) compared with the LJ results. The specificity was 94.7 % (18/19) compared with MGIT and 92.9 % (13/14) compared with LJ (Table 2) . Of 54 phenotypically RIF-resistant, TB-Biochip mutation-positive specimens, the most frequent rpoB gene mutation detected by TB-Biochip was rpoB531 Ser→Leu (94.4 %, 51/54); three specimens had concomitant mutations in rpoB533 Leu→Pro (n=2) or rpoB526_His→Pro (n=1). Two specimens had rpoB511_Leu→Pro mutation and one specimen bore two mutations (rpoB516 Asp→Gly and rpoB 511 Leu→Pro). For the detection of MTBC and RIF resistance, the TB-Biochip results were 100 % concordant with those obtained from direct and concentrated Xpert assays.
TB-Biochip detected mutations conferring isoniazid resistance in 98.2 % (54/55) phenotypically INH-resistant specimens by MGIT and 97.8 % (44/45) by LJ. TBBiochip did not detect INH resistance-conferring mutations phenotypically INH-resistant, TB-Biochip mutationpositive specimens, a specific mutation in the katG gene (315 Ser→Thr) was detected in the majority of specimens (98.4 %, 60/61) and 11/61 (18.0 %) specimens had a concomitant mutation in the inhA gene (five inhA15C→T and six inhA8T→G). A concomitant mutation in the intergenic region between ahpC and oxyR genes AhpC10 C→T was detected in one specimen. For one other specimen, the only mutation associated with resistance to INH was in the intergenic region between ahpC and oxyR genes, AhpC10 C→T. There were no indeterminate test results for TB-Biochip. 
Discussion
We validated the Xpert assay in two clinical laboratories in Russia, where the rate of TB and the proportion of drug resistance is relatively high, using single, pre-processed sputum specimens that were homogenized and split for testing by Xpert and conventional methods. For those specimens received at the CTRI laboratory, Xpert was also compared with TB-Biochip, an assay developed in Russia, using conventional laboratory methods as a reference standard.
A recent meta-analysis by Chang et al. [14] , including results from 18 unique studies and 10,224 pulmonary specimens of TB suspects, estimated the Xpert sensitivity for the detection of MTBC to be 90.4 % (95 % CI, 89.2-91.4 %), ranging from 73-74 % [15, 16] to 98-100 % [5, 17] across studies, depending on the study population. In our project, using culture positivity (liquid or solid) as the reference standard, the sensitivity of Xpert was 95.3 % for the detection of MTBC when tests were performed directly from unprocessed sputum and 94.5 % when a concentrated portion of the same specimen was tested, similar to findings reported by Boehme et al. [5] . Interestingly, the indeterminate rate dropped from 3.4 to 0 % when concentrated specimens were tested. Others have speculated that the higher viscosity of unprocessed sputum may contribute to the indeterminate results when these types of specimens are tested with Xpert [18] . The direct Xpert test was more sensitive (95.3 %) than direct smear (59.6 %), concentrated smear (85.3 %), or LJ culture (80.8 %), identifying 88.6 % of direct smear-negative, culture-positive specimens.
In the same meta-analysis [14] , the pooled specificity for MTBC detection was 98.4 % (95 % CI, 98.0-98.7 %). In our project, the direct Xpert assay had lower specificity for excluding MTBC (86.0 %) when compared with the culture result from the same specimen. The specificity of the direct Xpert test for the exclusion of TB, however, was 89.3 % when compared with a combined reference standard that included all available microbiology and radiography results, as well as the patient's final diagnosis. Among the six specimens with direct Xpert-positive results from patients with active TB ruled out, three were from patients who completed treatment for TB in the past. The presence of residual DNA from non-viable organisms in the specimen or a subclinical relapse, in which the bacillary burden was very low, could explain the positive results [14] . Complete specimen homogeneity may not have been achieved after processing with glass beads and prior to removing a portion for direct Xpert, resulting in Xpert-positive, culture-negative findings. Furthermore, delays in transport, additional sample decontamination using NaOH, or suboptimal culture conditions for resistant and/or unfit bacilli could have affected organism viability and growth in culture. False Xpert-positive results of the remaining three specimens are unexplained. It is well established that falsely positive NAAT results from amplicon contamination or cross-reaction with other species can occur [19, 20] . However, these possible explanations are unlikely, since Xpert has multiple features that may reduce false-positive results, such as its analytical specificity based on the molecular probe design, its closed-cartridge system that minimizes specimen-to-specimen cross-contamination, and an automated readout that minimizes user interpretation errors. Nevertheless, other possible causes such as specimen contamination at the time of collection, laboratory errors (mislabeling, pipetting, or clerical errors), or crosscontamination with a strongly positive specimen during the sample preparation process must be considered.
A principle advantage of the Xpert assay is the rapid detection of DNA mutations associated with rifampicin resistance for the timely initiation of treatment with second-line drugs and prevention of further transmission. This is especially important in Russia, where nearly all TB patients are hospitalized at least for the intensive phase of treatment. Chang and colleagues [14] reported pooled sensitivity and specificity for detecting rifampicin resistance of 94.1 % and 97.0 %, respectively. However, the accuracy for the detection of rifampicin resistance varied widely between reports, with ranges for the sensitivity from 80 % [21] to 97- 100 % [5, 6, 15] and the specificity from 72 % [21] to 98-100 % [5, 16, 22] . In our project, concordance of direct Xpert for the detection of mutations associated with RIF resistance, including sensitivity (98.2 %) and specificity (95.5 %), was higher with the MGIT DST method than with the absolute concentration method on LJ (sensitivity 90.0 % and specificity 93.3 %). The observed discordance between the two phenotypic DST methods re-emphasizes the complexities and limitations of conventional growth-based DST. Because of the high prevalence of rifampicin resistance in our sample (61.5 %), the positive predictive value for RIF resistance by Xpert was >95 % using phenotypic DST as a reference. Consistent with previous reports for high MDR TB prevalence settings [23, 24] , we found low rates of RIF resistance unaccompanied by resistance to isoniazid (5 %), so RIF resistance identified by Xpert can be a proxy for MDR TB in such populations until DST for isoniazid is completed. TB-Biochip performed well in detecting MTBC (sensitivity 97.3 %, specificity 78.1 %) compared with culture. The specificity for excluding TB was 100 % when compared with a combined reference standard including final diagnosis. Concordance between Xpert and TB-Biochip was 100 % for the detection of MTBC. The sensitivity and specificity of TBBiochip for RIF resistance was 100 % and 94.7 %, respectively, when compared with MGIT DST. Perfect concordance between TB-Biochip and Xpert for RIF resistance-conferring mutations may be explained by overlapping nucleotide sequences of probes for the rpoB gene in both assays. Comparable to previously published data [3, [25] [26] [27] , we report a sensitivity and specificity of 98.2 % and 78.6 % (compared to MGIT DST), respectively, for the detection of INH resistance by TB-Biochip. However, TB-Biochip is a fully manual test and requires specialized molecular laboratory infrastructure and specialized expertise, which limits use of this technology outside of central reference laboratories.
The incidence of TB is high and the prevalence of nontuberculous mycobacteria within Russia is low. Consequently, few specimens from patients without active TB and with NTM were included in this study, thereby, limiting the calculations of specificity. Duplicate specimens were obtained from 37 patients; these were not analyzed separately with methods for correlated data. Since this validation project was restricted to sputum specimens of ≥5 ml, the results may not apply to patients with less productive or non-productive cough. The human immunodeficiency virus (HIV) status of project patients was not collected, but HIV co-infection among TB patients in these two settings is relatively low (<5 %).
Despite these limitations, our project has several strengths. All tests were performed on the same specimen, which reduced variability caused by differences between specimens from the same patient, and all results were interpreted by staff members who were unaware of the results from other tests included in the project. The Xpert assay performance for the detection of MTBC was assessed using culture results from the same specimen, as well as its performance for the final diagnosis based on radiography, clinical judgment, and culture results from other specimens concurrently collected.
Based on these favorable results, the regional laboratory in Vladimir has launched a pilot point-of-care testing program, whereby Xpert testing has been implemented at three microscopy centers located within the region. Broadening the testing range beyond the low diagnostic capability of smear microscopy currently available at these centers to include Xpert testing may expedite the diagnosis and treatment of MDR-TB and, possibly, become an important modality for improving patient care and outcomes within the region.
Conclusion
This project describes the results of an algorithm for the validation of Cepheid® Xpert MTB/RIF® used by two laboratories within Russia, and a comparison of a portion of those results with the results obtained by TB-Biochip® MDR, a more technically demanding assay that requires both laboratory expertise and specialized facilities. The results demonstrate that a single unconcentrated sputum can be tested using Xpert with high sensitivity and specificity for the detection of Mycobacterium tuberculosis complex (MTBC) and rifampicin (RIF) resistance, equivalent to those obtained with TB-Biochip. Coupled with its simplicity and speed, the Xpert assay addresses two major gaps in settings with a high incidence of TB, a high prevalence of multidrug-resistant tuberculosis (MDR TB), or limited laboratory infrastructure: rapid, accurate detection of MTBC and simultaneous identification of RIF-resistant TB. This tool is especially valuable in settings without the capacity for concentrating sputum, without high-level biosafety facilities, or lacking in highly skilled laboratory staff.
